The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
BUSINESS
Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
Kowa said on April 5 that it has filed a new lawsuit against Towa Pharmaceutical seeking compensation of over 5.6 billion yen for damages relating to generic versions of its hypercholesterolemia treatment Livalo OD Tablets (pitavastatin). In the suit filed…
To read the full story
Related Article
- Towa Files Additional Request for Livalo Patent Invalidity in December 2020
April 16, 2021
- Kowa Sues Towa Again over Livalo Generics, Seeking Over 4.8 Billion Yen in Additional Damages for FY2017
April 7, 2020
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Kowa Sues Towa for Damages Caused by Livalo Generics
June 25, 2018
- Kowa Gets High Court Backing in Livalo Patent Suit
April 9, 2018
- Kowa Wins Livalo Patent Suit against Towa
October 13, 2017
BUSINESS
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
- FDA Accepts Astellas/Seagen’s Submissions for Padcev’s Full Approval, Label Expansion
April 21, 2021
- Oncolys to Codevelop COVID-19 Med with Shin Nippon Biomedical
April 21, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
April 20, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…